PRIMARY STUDY
Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model
Key Findings: The combination of cannabidiol (CBD) and β-caryophyllene (BCP) appears to be a safe and effective treatment option in this rat model for the management of chronic spinal cord injury (SCI) pain.
Type of Study: Animal Study
Study Result: Positive
Research Location(s): United States
Year of Pub: 2023
Cannabinoids Studied: Cannabidiol (CBD), AM-x Synthetic Cannabinoids, WIN-x Synthetic Cannabinoids
Phytocannabinoid Source: Not Applicable
Chemotype: Chemotype III
Terpenes Studied: ß-Caryophyllene
Receptors Studied: Opioid Receptor Mu , CB1 antagonist, CB2 antagonist
Route of Administration: , Injection
Citation: Eeswara A, Pacheco-Spiewak A, Jergova S, Sagen J. Combined non-psychoactive Cannabis components cannabidiol and β-caryophyllene reduce chronic pain via CB1 interaction in a rat spinal cord injury model. PLoS One. 2023 Mar 13;18(3):e0282920. doi: 10.1371/journal.pone.0282920. PMID: 36913400; PMCID: PMC10010563.
